Combination therapy of bupropion/naltrexone and GLP-1 receptor agonists showed a synergistic weight loss effect in individuals with obesity who responded poorly to GLP-1 monotherapy.
The addition of bupropion/naltrexone to glucagon-like peptide 1 receptor agonists leads to a further 4%-5% total body weight loss in patients with obesity, including those who show a poor response to initial GLP-1 monotherapy.Some patients with obesity experience suboptimal weight loss with GLP-1 monotherapy; however, adding treatments targeting multiple pathways may offer synergistic effects and improve outcomes.
They compared patients who continued receiving GLP-1 monotherapy with those who received add-on bupropion/naltrexone . Patients prescribed combination therapy were stratified into responders and nonresponders based on their initial response to GLP-1 monotherapy.Researchers included 415 patients with BMI ≥ 30 , of whom 320 continued receiving GLP-1 monotherapy and 95 received add-on bupropion/naltrexone ; the mean follow-up period was 510.9 days.
Obese Weight Loss GLP-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists Weight Management Receptors Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Body Mass Index BMI Board Certification Boards Board Recertification Adherence Adherence To Medication Issues For Patients Compliance Drug Compliance Treatment Adherence
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gene could unlock greater wheat yields for a growing populationA study from the University of Adelaide has discovered molecular pathways regulated by a gene traditionally used to control wheat-flowering behavior could be altered to achieve greater yields. The research was published in Current Biology.
Read more »
Counseling Patients Who Want to Try a GLP-1 RAPrimary care physicians are getting a lot of questions about these new weight loss agents. What concerns should be prioritized during a brief visit?
Read more »
Low Aspiration Risk in Adults on GLP-1s Undergoing Upper EndoscopyA retrospective study reported a 0.1% aspiration rate in adults taking GLP-1 receptor agonists and undergoing esophagogastroduodenoscopy, despite a 9.4% rate of retained gastric contents.
Read more »
Denmark to Restrict Ozempic, Other GLP-1 Drugs, to Treat Type 2 DiabetesDenmark will start putting patients suffering from type 2 diabetes on cheaper drugs before prescribing so-called GLP-1 drugs such as Novo Nordisk's Ozempic, the Danish...
Read more »
GI Complications With GLP-1s for Weight Loss: Reexamining the RisksAfter a 2023 study linked GLP-1s to an increased risk for pancreatitis, gastroparesis, and bowel obstruction, other researchers did a retrospective study to reexamine the association.
Read more »
Use of GLP-1 Meds Have Risen 7-Fold Among Young AmericansThe number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report finds.
Read more »